1-3 of 3
Marilyn J Siegel, MD
Close
Sort by
Journal Articles

A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

Todd A. Fehniger, MD/PhD, Sarah Larson, Kathryn Trinkaus, PhD, Marilyn J. Siegel, MD, David D. Hurd, MD, Kristie A. Blum, MD, Andre Goy, MD, Timothy S. Fenske, MD, Amanda Cashen, MD, Nina D. Wagner-Johnston, MD, Kenneth R. Carson, MD, Nancy L. Bartlett, MD
Journal: Blood
Blood (2012) 120 (21): 1623.
https://doi.org/10.1182/blood.V120.21.1623.1623
Published: 2012
Journal Articles

A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.

Todd A Fehniger, MD, PhD, Sarah Larson, Kathryn Trinkaus, PhD, Marilyn J Siegel, MD, Amanda F Cashen, MD, Kristie A Blum, MD, Timothy S. Fenske, MD, David D Hurd, MD, Andre Goy, MD, John F. DiPersio, MD, PhD, Nancy L Bartlett, MD
Journal: Blood
Blood (2009) 114 (22): 3693.
https://doi.org/10.1182/blood.V114.22.3693.3693
Published: 2009
Journal Articles

A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results

Todd A Fehniger, MD, PhD, Sarah Larson, BA, Kathryn Trinkaus, PhD, Marilyn J Siegel, MD, John F DiPersio, MD, PhD, Amanda F Cashen, MD, David D Hurd, MD, Kristie A Blum, MD, Nancy L Bartlett, MD
Journal: Blood
Blood (2008) 112 (11): 2595.
https://doi.org/10.1182/blood.V112.11.2595.2595
Published: 2008